Halogen Or Alkyl Group Of 1-5 Carbon Atoms Bonded Directly To The 5-position Of The Diazine Ring Patents (Class 536/28.52)
  • Patent number: 8993535
    Abstract: The compounds are of the class of pyrimidine analogs useful for treating cancer, for example:
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: March 31, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Janeta Popovici-Muller, Timothy J. Guzi, Kristin E. Rosner
  • Publication number: 20150037282
    Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Cyril B. DOUSSON, Gilles GOSSELIN, Claire PIERRA, David DUKHAN
  • Publication number: 20150005251
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Application
    Filed: June 24, 2014
    Publication date: January 1, 2015
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Patent number: 8912319
    Abstract: The present invention relates to methods of synthesizing 18F-FMAU. In particular, 18F-FMAU is synthesized using one-pot reaction conditions in the presence of Friedel-Crafts catalysts. The one-pot reaction conditions are incorporated into a fully automated cGMP-compliant radiosynthesis module, which results in a reduction in synthesis time and simplifies reaction conditions. The one-pot reaction conditions are also suitable for the production of 5-substituted thymidine or cytidine analogs. The products from the one-pot reaction (e.g. the labeled thymidine or cytidine analogs) can be used as probes for imaging tumor proliferative activity. More specifically, these [18F]-labeled thymidine or cytidine analogs can be used as a PET tracer for certain medical conditions, including, but not limited to, cancer disease, autoimmunity inflammation, and bone marrow transplant.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: December 16, 2014
    Assignee: University of Southern California
    Inventors: Zibo Li, Hancheng Cai, Peter S. Conti
  • Patent number: 8603998
    Abstract: In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: December 10, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Timothy J. Guzi, David A. Parry, Marc A. Labroli, Michael D. Dwyer, Kamil Paruch
  • Patent number: 8461124
    Abstract: Conformationally locked 2?,4?-carbocylic nucleosides with improved thermal and nuclease stability are disclosed. Oligonucleotides incorporating the locked nucleosides, and methods of treating disease states, are also disclosed.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: June 11, 2013
    Inventor: Jyoti Chattopadhyaya
  • Publication number: 20130078217
    Abstract: The present invention relates to 2?-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related ?-D and ?-L-nucleoside derivatives.
    Type: Application
    Filed: September 21, 2012
    Publication date: March 28, 2013
    Inventors: Guoqiang Wang, In Jong Kim, Yat Sun Or
  • Patent number: 8361988
    Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: January 29, 2013
    Assignee: Institut de Recherches Cliniques de Montreal
    Inventor: Yvan Guindon
  • Publication number: 20120263678
    Abstract: Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 18, 2012
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Aesop Cho, Choung U. Kim, Thorsten A. Kirschberg, Michael R. Mish, Neil Squires
  • Publication number: 20120237480
    Abstract: The present invention relates to 2?-allene-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related ?-D and ?-L-nucleoside derivatives.
    Type: Application
    Filed: March 16, 2012
    Publication date: September 20, 2012
    Inventors: YAT SUN OR, Jun Ma, Guoqiang Wang, In Jong Kim, Jiang Long, Yao-Ling Qiu
  • Publication number: 20120232029
    Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.
    Type: Application
    Filed: December 13, 2011
    Publication date: September 13, 2012
    Applicant: Pharmasset, Inc.
    Inventors: MICHAEL JOSEPH SOFIA, Jinfa Du
  • Patent number: 8236945
    Abstract: Process for preparing a compound of the formula (I) R1-S(O)x—S(O)yR2 in which R1 represents a molecular hydrocarbon radical which can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si and X, where X represents a halogen; R2, independently of R1, represents a carbon-containing group or a molecular hydrocarbon radical which can be substituted and/or interrupted by one or more atoms and/or by one or more groups containing one or more atoms, said atoms being selected from N, O, P, S, Si and X, where X represents a halogen, and x and y are selected from 0 and 1 in such a way that the sum of x and y is not more than 1, characterized in that a compound of formula (II) R1-S(O)x—R3-Si(R4)(R5)(R6) in which R3 represents a hydrocarbon chain of two carbon atoms, which is optionally unsaturated and/or substituted, and R4, R5 and R6, which are identical or different, each represent, independently of one another, a
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: August 7, 2012
    Assignee: Universite Joseph Fourier (Grenoble1)
    Inventors: Jean-Luc Decout, Beatrice Gerland, Jerome Desire
  • Patent number: 8227594
    Abstract: Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: July 24, 2012
    Inventors: Rakesh Kumar, Babita Agrawal, D. Lorne J. Tyrrell
  • Patent number: 8193339
    Abstract: This invention relates to a process of stereoselectively synthesizing a ?-nucleoside compound of formula (I): wherein R1, R2, and B are as defined in the specification; each of R3 and R4, independently, is H or fluoro. The process includes reacting, in the presence of a transition metal salt, a tetrahydrofuran compound of formula (II): wherein R1, R2, and L are as defined in the specification, with a nucleobase derivative; and each of R3 and R4, independently, is H or fluoro.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: June 5, 2012
    Assignee: Pharmaessentia Corp.
    Inventors: Chi-Yuan Chu, Wei-Der Lee, Wensen Li, Chan Kou Hwang
  • Publication number: 20110300142
    Abstract: The invention relates to the use of 1-(?-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.
    Type: Application
    Filed: May 26, 2008
    Publication date: December 8, 2011
    Inventors: Leif G. Salford, Bertil Persson, Hans Olov Sjögren, Bengt Widegren
  • Publication number: 20110275124
    Abstract: This invention relates to the field of nucleic acid chemistry, more specifically to the field of compositions of matter that comprise triphosphates of modified 2?-deoxynucleosides and oligonucleotides that are formed when these are appended to the 3?-end of a primer, wherein said modifications comprise NH2 moiety attached to their 3?-hydroxyl group and a fluorescent species in a form of a tag affixed to the nucleobase via a linker that can be cleaved. Such compositions and their associated processes enable and improve the sequencing of oligonucleotides using a strategy of cyclic reversible termination, as outlined in U.S. Pat. No. 6,664,079. Most specifically, the invention concerns compositions of matter that are 5?-triphosphates of ribo- and 2?-deoxyribonucleosides carrying detectable tags and oligonucleotides that might be derived from them.
    Type: Application
    Filed: March 23, 2009
    Publication date: November 10, 2011
    Inventors: Steven A. Benner, Daniel Hutter, Nicole Aurora Leal, Fei Chen
  • Publication number: 20110092451
    Abstract: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3? position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.
    Type: Application
    Filed: March 18, 2009
    Publication date: April 21, 2011
    Applicant: INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL
    Inventor: Yvan Guindon
  • Publication number: 20110054165
    Abstract: The invention provides a novel class of xanthene dyes, some of which are functionalized to allow their coupling to conjugation partners of interest, e.g. biomolecules, drugs, toxins and the like. Also provided are conjugates of the dyes, methods of preparing and using the dyes and their conjugates and kits including the dyes and their conjugates.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 3, 2011
    Applicant: BIOSEARCH TECHNOLOGIES, INC.
    Inventors: MARK REDDINGTON, MATT LYTTLE
  • Publication number: 20110040082
    Abstract: This Divisional application of patent application Ser. No. 10/768,996, entitled “Novel Oligonucleotides And Related Compounds” discloses a class of chemical compounds which have been demonstrated to possess cancer fighting properties. The parent application disclosed oligonucleotides for selectively killing cancerous cells over noncancerous cells by incorporating and covalently linking antimetabolite prodrugs via CpG moieties, for the anitmetabolite Gemcitabine and other compounds with known cancer fighting properties. This application discloses modifications of Gemcitabine for incorporation into CpG oligonucleotides for improved biochemical and biological properties.
    Type: Application
    Filed: October 22, 2010
    Publication date: February 17, 2011
    Inventor: Suresh C. Srivastava
  • Patent number: 7772208
    Abstract: A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a ?-L- or ?-D-2?,3?-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: August 10, 2010
    Assignees: Pharmasset, Inc., Leland Stanford Junior University, Emory University
    Inventors: Raymond Schinazi, Robert Striker, Junxing Shi
  • Patent number: 7691826
    Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: April 6, 2010
    Assignee: Lipoxen Technologies Limited
    Inventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
  • Patent number: 7601702
    Abstract: Deoxyuridine derivatives of Formula (I?); where A is O, S or CH2; B is O, S or CHR3; R1 is H, or various substituents; R2 is H, F; R3 is H, F, OH, NH2; or R2 and R3 together form a chemical bond; D is —NHCO—, —CONH—, —O—, —C(?O)—, —CH?CH, —C?C—, —NR5—; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system have utility in the prophylaxis of treatment of parasitic diseases such as malaria.
    Type: Grant
    Filed: January 6, 2005
    Date of Patent: October 13, 2009
    Assignee: Medivir AB
    Inventors: Ian Gilbert, Corinne Nguyen, Gian Filippo Ruda, Alessandro Schipani, Ganasan Kasinathan, Nils-Gunnar Johansson, Dolores Gonzalez Pacanowska
  • Patent number: 7589077
    Abstract: Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: September 15, 2009
    Inventors: Rakesh Kumar, Babita Agrawal, D. Lorne J. Tyrrell
  • Patent number: 7585851
    Abstract: The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compound and compositions of 3?-esters of 2?-deoxy-?-L-pyrimidine nucleosides are disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents. Compound and compositions of 3?,5?-diesters of 2?-deoxy-?-L-pyrimidine nucleosides are also disclosed, which can be administered either alone or in combination with other anti-hepatitis B agents.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: September 8, 2009
    Assignees: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, L'Universite Montpellier II
    Inventors: Martin L. Bryant, Gilles Gosselin, Jean-Louis Imbach
  • Publication number: 20090149416
    Abstract: Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.
    Type: Application
    Filed: February 10, 2009
    Publication date: June 11, 2009
    Inventors: Dennis C. Liotta, Shuli Mao, Michael Hager
  • Patent number: 7544794
    Abstract: This invention relates to the field of nucleic acid chemistry, more specifically to the field of compositions and processes that are nucleic acid analogs. More specifically, this invention relates to compositions that allow the sequencing of oligonucleotides by synthesis, and processes for sequencing by synthesis that exploit these compositions. Most specifically, the instant invention discloses compositions of matter that are 5?-triphosphates of ribo- and 2?-deoxyribonucleosides wherein the 3?-OH group is replaced by a 3?-ONHR group in the alpha configuration, wherein R is either a H or CH3 group. Also disclosed are these triphosphates where the nucleobase carries, via a linker, a reporter groups, such as a fluorescent species that can be used in single- or multi-copy DNA sequencing, or a tag that can be visualized by ultramicroscopy. Also disclosed are processes that use these compositions to do sequencing by synthesis.
    Type: Grant
    Filed: March 11, 2006
    Date of Patent: June 9, 2009
    Inventor: Steven Albert Benner
  • Publication number: 20080300399
    Abstract: An intermediate (2) useful in making capecitabine can be formed without the use, or presence, of a silylation agent.
    Type: Application
    Filed: June 2, 2008
    Publication date: December 4, 2008
    Inventor: Gerrit J. B. Ettema
  • Patent number: 7365188
    Abstract: The present invention provides a process for producing a N4-acyl-5?-deoxy-5-fluorocytidine compound of the formula: where R2 is alkyl, cycloalkyl, aralkyl, aryl, or alkoxy.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: April 29, 2008
    Assignee: Roche Colorado Corporation
    Inventors: Christopher R. Roberts, Jim-wah Wong
  • Patent number: 7276228
    Abstract: Methods are provided for treating hematological disorders by inhibition of DNA hypomethylation and histone deacetylase. Such disorders include, for example, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia. The methods comprise: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: October 2, 2007
    Assignee: SuperGen, Inc.
    Inventor: Jorge F. DiMartino
  • Patent number: 7148207
    Abstract: This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: December 12, 2006
    Assignee: Schering Aktiengesellschaft
    Inventors: Wolfgang Heil, Ulf Tistam, Ralph Lipp, Johannes-Wilhelm Tack
  • Patent number: 6933288
    Abstract: This invention is directed to novel pyranosyl cytosine compounds depicted graphically as structure I. This invention is further directed to a unique methodology for their preparation using solid-phase methodology. These hexopyranosyl cytosine derived natural product analogs share their parent compounds broad-spectrum antimicrobial and anti-fungal profile and represent a vast, novel compound class of 50S rRNA directed inhibitors of protein translation.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: August 23, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Eric E. Swayze, Richard H. Griffey
  • Patent number: 6905669
    Abstract: Compositions and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: June 14, 2005
    Assignee: SuperGen, Inc.
    Inventor: Jorge F. DiMartino
  • Patent number: 6894159
    Abstract: The present invention relates to a novel and improved process for preparing 2?-fluoro-5-methyl-?-L-arabinofuranosyluridine represented by formula (1) which shows anti-viral activity, especially potent anti-viral activity against hepatitis B-virus and Epstein-Barr virus:
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: May 17, 2005
    Assignee: The University of Georgia Research Foundation
    Inventors: Chung K. Chu, Jinfa Du, Yongseok Choi
  • Patent number: 6884880
    Abstract: A process for substantially enhancing the regio and stereoselective synthesis of 9-?-anomeric nucleoside analogs is described. The introduction of the sugar moiety onto a 6-substituted purine base was preformed so that only the 9-?-D- or L-purine nucleoside analogs were obtained. This regio and stereoselective introduction of the sugar moiety allows the synthesis of nucleoside analogs and in particular 2?-deoxy, 3?-deoxy, 2?-deoxy-2?-?-fluoro and 2?,3?-dideoxy-2?-?-fluoro purine nucleoside analogs in high yield without virtually any formation of the 7-positional isomers. The compounds are drugs or intermediates to drugs.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: April 26, 2005
    Assignee: Ash Stevens, Inc.
    Inventors: Pranab K. Gupta, Stephen A. Munk
  • Patent number: 6870048
    Abstract: The present invention is directed to the process for the preparation of 2?-deoxy-2?-halo-?-L-arabinofuranosyl nucleosides, and in particular, 2?-deoxy-2?-fluoro-?-L-arabinofuranosyl thymine (L-FMAU), from L-arabinose, which is commercially available and less expensive than L-ribose or L-xylose, in ten steps. All of the reagents and starting materials are inexpensive and no special equipment is required to carry out the reactions.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: March 22, 2005
    Assignee: Triangle Pharmaceuticals
    Inventor: Marcos Sznaidman
  • Publication number: 20040121979
    Abstract: The present invention relates to novel uridine esters of the general formula (I) wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R′ represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.
    Type: Application
    Filed: October 29, 2003
    Publication date: June 24, 2004
    Inventor: Rudy Susilo
  • Publication number: 20040077586
    Abstract: The present invention relates to the preparation of (E)-5-(2-bromovynyl)-2′-deoxyuridine (Brivudine) characterized in that halogen-free solvents selected form esters or cyclic ethers are used in the bromination step of 5-ethyl-2′deoxyuridine diacy-late. The use of said solvents is advantageous in respect of toxicity, discharge costs and environment protection.
    Type: Application
    Filed: August 26, 2003
    Publication date: April 22, 2004
    Inventors: Aldo Salimbeni, Carlo Alberto Maggi, Stefano Manzini, Damiano Turozzi
  • Patent number: 6635753
    Abstract: There are disclosed novel Stavudine solvates as follows: Stavudine NN-dimethyllacetamide solvates; Stavudine NN-dimethylacrylamide solvates and Stavudine NN-dimethylpropionamide solvates and processes for producing Stavudine NN-dimethylacetamide solvates, Stavudine NN dimethylacrylamide solvates and Stavudine NN dimethylpropionamide solvates which results in pure Stavudine.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: October 21, 2003
    Assignee: Brantford Chemicals Inc.
    Inventors: Bruno K. Radatus, K. S. Keshava Murthy
  • Patent number: 6617437
    Abstract: Compounds having particular interest as labels and various novel uses in diagnostics and therapeutics are provided which have structure (1) wherein R1 is a binding partner, a linker or H; a and b are 0 or 1, provided that the total of a and b is 0 or 1; A is N or C; X is S, O, —C(O)—, NH or NCH2R6; Y is —C(O)—; Z is taken together with A to form an aryl or heteroaryl ring structure comprising 5 or 6 ring atoms wherein the heteroaryl ring comprises a single O ring heteroatom, a single N ring heteroatom, a single S ring heteroatom, a single O and a single N ring heteroatom separated by a carbon atom, a single S and a single N ring heteroatom separated by a carbon atom, 2 N ring heteroatoms separated by a carbon atom, or 3 N ring heteroatoms at least two of which are separated by a carbon atom, and wherein the aryl or heteroaryl ring carbon atoms are unsubstituted with other than H or at least 1 nonbridging ring carbon atom is substituted with R6 or ═O; R6 is
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: September 9, 2003
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Robert J. Jones, Kuei-Ying Lin
  • Publication number: 20030124054
    Abstract: An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: 1
    Type: Application
    Filed: September 23, 2002
    Publication date: July 3, 2003
    Inventors: Jun Toyohara, Akio Hayashi
  • Patent number: 6579976
    Abstract: There can be provided an excellent industrial process for producing compounds having sugar-moiety hydroxyl groups or halogen atoms reduced in nucleic acids or in derivatives thereof by allowing O-thiocarbonyl derivatives of sugar-moiety hydroxyl groups or allowing halogenated derivatives in the sugar-moiety, in the nucleic acids or in derivatives thereof to react with any one of hypophosphorous acids (including salts thereof) and phosphites (esters) which are inexpensive, non-toxic and safely usable as radical reducing agents in industrial scale, in the presence of a radical reaction initiator. The process of the present invention is an industrially useful and highly safe process for reducing sugar-moiety hydroxyl groups and halogen atoms in nucleic acids or derivatives thereof (including nucleic acid-related compounds) at low costs.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: June 17, 2003
    Assignee: Ajinomoto Co., Inc.
    Inventors: Satoshi Takamatsu, Satoshi Katayama, Naoko Hirose, Kunisuke Izawa
  • Patent number: 6566344
    Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentoftiranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: May 20, 2003
    Assignee: Idenix Pharmaceuticals, Inc.
    Inventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
  • Publication number: 20030087874
    Abstract: The invention provides compounds of the Formula 1 1
    Type: Application
    Filed: April 25, 2002
    Publication date: May 8, 2003
    Applicant: American Cyanamid Company
    Inventors: Ayako Yamashita, Emily Boucher Norton
  • Patent number: 6512107
    Abstract: The present invention relates to a novel and improved process for preparing 2′-fluoro-5-methyl-&bgr;-L-arabinofuranosyluridine represented by formula (I) which shows anti-viral activity, especially potent anti-viral activity against hepatitis B-virus and Epstein-Barr virus:
    Type: Grant
    Filed: July 23, 1998
    Date of Patent: January 28, 2003
    Assignee: The University of Georgia Research Foundation
    Inventors: Chung K. Chu, Jinfa Du, Yongseok Choi
  • Patent number: 6458773
    Abstract: Compounds and pharmaceutical compositions active against hepatitis B virus are provided, as is a method for the treatment of hepatitis B virus infection in humans and other host animals is provided comprising administering an effective amount of a &bgr;-L-(2′or 3′-azido)-2′,3′-dideoxy-5-fluorocytosine of the formula wherein R is H, acyl, monophosphate, diphosphate, or triphosphate, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug), and R′is H, acyl, or alkyl.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: October 1, 2002
    Assignees: Emory University, Centre National de la Recherche Scientifique, UAB Research Foundation
    Inventors: Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi, Raymond F. Schinazi
  • Patent number: 6458772
    Abstract: Compounds of the formula I or corresponding monohydroxynucleoside derivatives wherein: R1 is hydroxy, amino or carboxy: optionally having esterified/amide bonded thereon; a C4-C22 saturated or unsaturated, optionally substituted fatty acid or alcohol, or an aliphatic L-amino acid; R2 is the residue of an aliphatic L-amino acid; L1 is a trifunctional linker group; L2 is absent or a difunctional linker group; and pharmaceutically acceptable salts thereof have favorable pharmacological properties and are antivirally active.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: October 1, 2002
    Assignee: Medivir AB
    Inventors: Xiao-Xiong Zhou, Nils Gunnar Johansson, Horst Wahling, Christian Sund, Hans Wallberg, Lourdes Salvador, Stefan Lindstrom, Christer Sahlberg
  • Patent number: 6437118
    Abstract: The invention relates to a process for the preparation of vinyl pyrimidines of the formula I wherein R1 is hydrogen or a carboxylic ester group, and R2 is hydrogen or a group of the formula (a) wherein Ra is hydrogen, a protecting group or a group easily hydrolyzable under physiological conditions, by reacting a compound of the formula II wherein R21 is hydrogen or a group (a) wherein hydroxy groups are optionally protected, R3 is bromo, chloro or iodo, and R1 is as above, with a vinyl borane compound in the presence of a Pd complex and a base, and optionally, further reacting a product of formula I wherein R2 is hydrogen with a compound of the formula IV wherein Rb is a hydroxy protecting group and Z is a leaving group, in the presence of a Lewis acid catalyst.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: August 20, 2002
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Püntener, Michelangelo Scalone
  • Patent number: 6403568
    Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: June 11, 2002
    Assignee: Yamasa Corporation
    Inventors: Hiroshi Ohrui, Shiro Shigeta, Eiichi Kodama, Haruhiko Machida, Satoru Kohgo, Hiroaki Mitsuya
  • Patent number: 6380368
    Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: April 30, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brian Froehler, Rick Wagner, Mark Mattencci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
  • Patent number: RE38090
    Abstract: The invention relates to a 3′-substituted nucleoside derivative represented by the following general formula (1): wherein B means a nucleic acid base which may have a substituent, Z represents a lower alkynyl or lower alkenyl group which may be substituted by a group represented by the formula: in which Ra, Rb and Rc are individually a lower alkyl group or a phenyl group, or an oxiranyl group which may have at least one lower alkyl group, R1 and R2 individually represent H or an ester-forming residue capable of easily leaving in a living body, and R3 is H, a mono- or polyphosphoric acid residue, or an ester-forming residue capable of easily leaving in a living body, with the proviso that the sugar moiety is ribose, or a pharmaceutically acceptable salt thereof. The 3′-substituted nucleoside derivative according to the invention has an excellent antitumor activity and is hence useful for treatment for and prevention of cancers.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: April 22, 2003
    Assignees: Taiho Pharmaceutical Co., Ltd.
    Inventors: Akira Matsuda, Takuma Sasaki